LTX-315 is under clinical development by Lytix Biopharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect LTX-315’s likelihood of approval (LoA) and phase transition for Soft Tissue Sarcoma took place on 22 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LTX-315 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
LTX-315 (Oncopore) is under development for the treatment of transdermally accessible tumors including malignant melanoma, head and neck squamous cell carcinoma, lymphoma, soft tissue sarcoma basal cell and squamous cell carcinomas. The drug is formulated as injection and administered through intratumoral route. LTX-315 (Oncopore) is a chemically modified cationic cytolytic nonapeptide which is equally active against drug-sensitive and drug-resistant cancer cells. It is derived from the naturally occurring antimicrobial peptide, bovine lactoferricin. It was also under development for carcinoma and liver cancer.
It was under development for the treatment of non-small cell lung cancer, urothelial carcinoma, gastric cancer, gastroesophageal junction adenocarcinoma, triple-negative breast cancer, hepatocellular carcinoma, renal cell carcinoma, Merkle cell carcinoma, small cell lung cancer, squamous cell carcinoma of esophagus, esophageal squamous cell carcinoma (ESCC), cervical cancer.
Lytix Biopharma overview
Lytix Biopharma (Lytix) is a biotechnology company that discovers and develops drugs for cancer. It is investigating LTX-315, an oncolytic peptide to treat solid tumors by generating an immune response against a broad antigen repertoire without the need for identification of the antigens. The company is also evaluating LTX-401 program targeting patients with hepatocellular carcinoma, liver metastases and other deep-seated lesions. It utilizes its proprietary in situ vaccination technology to inject molecules into solid tumors and kill cancer cells by activating the patient’s immune system and enable killer T cells to recognize and eliminate cancer cells. Lytix is headquartered in Oslo, Norway.
Quick View LTX-315 LOA Data
|Highest Development Stage|